The CATALINA study (s64324)

  • Research type

    Research Study

  • Full title

    The CATALINA Study - A European multi-centre prospective cohort study \nin patients hospitalized for an acute exacerbation of COPD

  • IRAS ID

    322442

  • Contact name

    Mona Bafadhel

  • Contact email

    mona.bafadhel@kcl.ac.uk

  • Sponsor organisation

    UZ Leuven

  • Clinicaltrials.gov Identifier

    NCT05008081

  • Duration of Study in the UK

    5 years, 0 months, 0 days

  • Research summary

    Exacerbations of chronic obstructive pulmonary disease (COPD) requiring hospitalisation are serious and complex events that are poorly defined, with treatment and follow-up varying greatly across Europe. They are associated with significant morbidity and high mortality (11% in the first 3 months). This is mainly due to the poor characterization of exacerbations and a uniform approach of treating everyone with systemic corticosteroids and antibiotics, without taking into account the vast differences in event cause, course and outcomes. There is a high clinical need for deeper understanding of these events, as well as tailoring treatment and follow-up to the needs of the patient. \n\nThe CATALINA study is a clinical study in patients hospitalised for an acute COPD exacerbation, which aims to develop a detailed European data and biobank enabling accurate characterization of exacerbations. The objective is to enrol 1000 patients with 1-year follow-up by the end of 2025, in 20 centres across Europe and the UK. Eligible participants are adult patients diagnosed with COPD, hospitalised for a severe exacerbation and treated with antibiotics and/or systemic corticosteroids.\n\nThe study is designed to be embedded in routine clinical care following a severe exacerbation requiring hospitalisation, and data and sample collection was based on a prior European consensus obtained from COPD experts and patients on which clinical assessments to perform during and after the acute event. During 1-year study participation, clinical data and biological samples (blood, sputum, nasal swab and urine) are collected during 6 scheduled study visits. Three study visits occur during hospitalisation (enrolment within 48-hours of hospital admission, at 72-hours after enrolment, day of discharge). After hospital discharge, 3 follow-up study visits are planned during routine clinical follow-up (at 3, 6 and 12 months). In case of a first re-admission for respiratory reasons during the follow-up period, the first 3 study visits are repeated.\n

  • REC name

    South Central - Oxford B Research Ethics Committee

  • REC reference

    23/SC/0065

  • Date of REC Opinion

    21 Mar 2023

  • REC opinion

    Favourable Opinion